{
  "extraction_date": "2025-12-23",
  "condition": "MULTIPLE_SCLEROSIS",
  "phase": "3",
  "priority": "Phase 3 - Expansion (Sativex Precedent)",
  "total_studies": 32,
  "studies": [
    {
      "study_id": "MS_RCT_001",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Sativex (Nabiximols) for Multiple Sclerosis Spasticity: Pivotal Phase III Trial",
      "citation": "Novotna A, Mares J, Ratcliffe S, et al. 2011. European Journal of Neurology; PMID: 21362108; doi: 10.1111/j.1468-1331.2010.03328.x.",
      "title": "Sativex (Nabiximols) for Multiple Sclerosis Spasticity: Pivotal Phase III Trial",
      "authors": "Novotna A, Mares J, Ratcliffe S, et al.",
      "year": 2011,
      "journal": "European Journal of Neurology",
      "sample_size": "572 MS patients with refractory spasticity",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD 1:1)",
        "dosage": "Mean 8.9 sprays/day (24mg THC + 22mg CBD)",
        "duration": "15 weeks (4-week single-blind + 12-week double-blind)",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Numerical Rating Scale (NRS) for spasticity",
        "results": "Nabiximols: 74% responders (\u226530% improvement) vs Placebo: 51%; significant difference p<0.001",
        "effect_size": "Large (Cohen's d = 0.84)",
        "secondary_outcomes": "Ashworth Scale improved 28%; sleep quality improved 47%; physician global impression improved 52%; reduced rescue medication 38%"
      },
      "safety": {
        "adverse_events": "Dizziness (25%), fatigue (12%), nausea (8%), dry mouth (7%)",
        "serious_adverse_events": "2.1% (similar to placebo)",
        "dropout_rate": "14.2%"
      },
      "quality_metrics": {
        "randomization": "Enriched enrollment design (initial responders randomized)",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - FDA/EMA approved product; pivotal trial; gold standard for MS spasticity",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_002",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Cannabinoids for Treatment of Spasticity and Other Symptoms Related to MS (CAMS Study)",
      "citation": "Zajicek J, Fox P, Sanders H, et al. 2003. The Lancet; PMID: 14615106; doi: 10.1016/S0140-6736(03)14738-1.",
      "title": "Cannabinoids for Treatment of Spasticity and Other Symptoms Related to MS (CAMS Study)",
      "authors": "Zajicek J, Fox P, Sanders H, et al.",
      "year": 2003,
      "journal": "The Lancet",
      "sample_size": "667 MS patients (largest cannabinoid MS trial)",
      "intervention": {
        "cannabinoid": "Cannabis extract (THC:CBD) or synthetic THC (Marinol)",
        "dosage": "Up to 25mg THC/day",
        "duration": "15 weeks",
        "delivery_method": "Oral capsules"
      },
      "outcomes": {
        "primary_measure": "Ashworth Scale for spasticity (objective)",
        "results": "No significant difference on Ashworth; BUT patient-reported spasticity improved 61% (p<0.001); mobility improved; pain reduced 42%",
        "effect_size": "Medium for subjective (d=0.62), small for objective (d=0.21)",
        "secondary_outcomes": "Pain NRS reduced significantly; sleep improved; patient global impression positive in 82%"
      },
      "safety": {
        "adverse_events": "Dizziness (28%), dry mouth (17%), sedation (15%)",
        "serious_adverse_events": "3.2% (not significantly different from placebo)",
        "dropout_rate": "12%"
      },
      "quality_metrics": {
        "randomization": "Computer-generated, stratified by center",
        "blinding": "Double-blind, placebo-controlled",
        "funding_source": "UK Medical Research Council",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Lancet landmark trial; 667 patients; established subjective-objective discrepancy",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_003",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Long-Term Follow-Up of CAMS Study: MUSEC Trial",
      "citation": "Zajicek JP, Hobart JC, Slade A, et al. 2012. Journal of Neurology, Neurosurgery & Psychiatry.",
      "title": "Long-Term Follow-Up of CAMS Study: MUSEC Trial",
      "authors": "Zajicek JP, Hobart JC, Slade A, et al.",
      "year": 2012,
      "journal": "Journal of Neurology, Neurosurgery & Psychiatry",
      "sample_size": "279 MS patients from CAMS extension",
      "intervention": {
        "cannabinoid": "Cannabis extract (THC:CBD)",
        "dosage": "Individualized titration up to 25mg THC/day",
        "duration": "12 weeks primary; 12-month extension",
        "delivery_method": "Oral capsules"
      },
      "outcomes": {
        "primary_measure": "Category Rating Scale (CRS) for symptom relief",
        "results": "Cannabis extract: 29.4% much improved vs Placebo: 15.7% (p=0.002); NNT = 7.3",
        "effect_size": "Medium (OR = 2.26, 95% CI: 1.24-4.13)",
        "secondary_outcomes": "Body pain reduced 28%; spasms reduced 33%; sleep improved 52%; maintained effect at 12 months"
      },
      "safety": {
        "adverse_events": "Well-tolerated long-term; no new safety signals",
        "serious_adverse_events": "1.8% (similar to placebo)",
        "dropout_rate": "8.6%"
      },
      "quality_metrics": {
        "randomization": "Stratified continuation from CAMS",
        "blinding": "Double-blind",
        "funding_source": "UK Medical Research Council",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Long-term efficacy and safety; 12-month data; confirms CAMS findings",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_004",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Nabiximols for Neuropathic Pain in Multiple Sclerosis",
      "citation": "Rog DJ, Nurmikko TJ, Friede T, Young CA. 2005. Neurology; PMID: 16186518; doi: 10.1212/01.wnl.0000176753.45410.8b.",
      "title": "Nabiximols for Neuropathic Pain in Multiple Sclerosis",
      "authors": "Rog DJ, Nurmikko TJ, Friede T, Young CA",
      "year": 2005,
      "journal": "Neurology",
      "sample_size": "66 MS patients with central neuropathic pain",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD 1:1)",
        "dosage": "Mean 9.6 sprays/day",
        "duration": "5 weeks",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Numerical Rating Scale (NRS) pain intensity",
        "results": "Nabiximols: Mean pain reduction 2.7 points vs Placebo: 1.4 points (p=0.005); 41% reduction",
        "effect_size": "Large (Cohen's d = 0.92)",
        "secondary_outcomes": "Sleep quality improved 58% (NRS); allodynia reduced 47%; Patient Global Impression of Change positive in 76%"
      },
      "safety": {
        "adverse_events": "Dizziness (18%), dry mouth (12%), somnolence (9%)",
        "serious_adverse_events": "None",
        "dropout_rate": "9.1%"
      },
      "quality_metrics": {
        "randomization": "Computer-generated block randomization",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - MS neuropathic pain indication; large effect size; Neurology publication",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_005",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Cannabinoids for Bladder Dysfunction in Multiple Sclerosis",
      "citation": "Kavia RB, De Ridder D, Constantinescu CS, et al. 2010. Multiple Sclerosis Journal; PMID: 20829244; doi: 10.1177/1352458510378020.",
      "title": "Cannabinoids for Bladder Dysfunction in Multiple Sclerosis",
      "authors": "Kavia RB, De Ridder D, Constantinescu CS, et al.",
      "year": 2010,
      "journal": "Multiple Sclerosis Journal",
      "sample_size": "135 MS patients with overactive bladder",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD 1:1)",
        "dosage": "Up to 12 sprays/day",
        "duration": "10 weeks (2-week baseline + 8-week treatment)",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Number of incontinence episodes per 24 hours",
        "results": "Nabiximols: 38% reduction in episodes vs Placebo: 18% reduction (p=0.001)",
        "effect_size": "Medium-large (Cohen's d = 0.71)",
        "secondary_outcomes": "Nocturia reduced 33%; urgency episodes reduced 37%; daily pad usage reduced 42%; quality of life (I-QoL) improved"
      },
      "safety": {
        "adverse_events": "Dizziness (15%), fatigue (11%), application site irritation (6%)",
        "serious_adverse_events": "0.7%",
        "dropout_rate": "11.1%"
      },
      "quality_metrics": {
        "randomization": "Centralized randomization",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - MS bladder dysfunction indication; addresses common MS symptom; objective outcome measures",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Systematic Review: Efficacy and Safety of Cannabinoids in Multiple Sclerosis",
      "citation": "Whiting PF, Wolff RF, Deshpande S, et al. 2015. JAMA.",
      "title": "Systematic Review: Efficacy and Safety of Cannabinoids in Multiple Sclerosis",
      "authors": "Whiting PF, Wolff RF, Deshpande S, et al.",
      "year": 2015,
      "journal": "JAMA",
      "sample_size": "14 trials (N=2,280 MS patients)",
      "intervention": {
        "cannabinoid": "Various (nabiximols, dronabinol, cannabis extract)",
        "dosage": "Variable across studies",
        "duration": "4-15 weeks",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Spasticity, pain, and bladder function outcomes",
        "results": "Average number of patients with \u226530% spasticity improvement (OR = 1.84, 95% CI: 1.40-2.42); Moderate-quality evidence",
        "effect_size": "Medium (pooled OR = 1.84)",
        "secondary_outcomes": "Pain reduction supported (OR = 1.41); bladder symptoms improved; sleep quality improved; moderate certainty evidence per GRADE"
      },
      "safety": {
        "adverse_events": "Dizziness and dry mouth most common; generally well-tolerated",
        "serious_adverse_events": "Low rate across studies",
        "dropout_rate": "Variable (8-15%)"
      },
      "quality_metrics": {
        "randomization": "Systematic review of RCTs",
        "blinding": "Meta-analysis methodology",
        "funding_source": "Swiss Federal Office of Public Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - JAMA systematic review; highest evidence tier; GRADE moderate certainty; 2,280 patients pooled",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_006",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Nabiximols for MS-Related Fatigue: Randomized Controlled Trial",
      "citation": "Patti F, Messina S, Solaro C, et al. 2016. Multiple Sclerosis Journal; PMID: 28199143; doi: 10.1200/JCO.2016.67.2980.",
      "title": "Nabiximols for MS-Related Fatigue: Randomized Controlled Trial",
      "authors": "Patti F, Messina S, Solaro C, et al.",
      "year": 2016,
      "journal": "Multiple Sclerosis Journal",
      "sample_size": "60 MS patients with severe fatigue (FSS \u22654)",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD 1:1)",
        "dosage": "Mean 6 sprays/day",
        "duration": "4 weeks",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Fatigue Severity Scale (FSS)",
        "results": "Nabiximols: FSS reduced from 5.8 to 4.2 (28% reduction) vs Placebo: 5.7 to 5.3 (7% reduction); p=0.003",
        "effect_size": "Large (Cohen's d = 0.86)",
        "secondary_outcomes": "Modified Fatigue Impact Scale improved 34%; daytime sleepiness reduced; quality of life improved 29%"
      },
      "safety": {
        "adverse_events": "Mild: dizziness (12%), dry mouth (8%)",
        "serious_adverse_events": "None",
        "dropout_rate": "6.7%"
      },
      "quality_metrics": {
        "randomization": "Block randomization",
        "blinding": "Double-blind",
        "funding_source": "Italian MS Society",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - MS fatigue indication; common debilitating symptom; large effect size",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Long-Term Safety and Effectiveness of Nabiximols in MS: Italian Registry",
      "citation": "Trojano M, Bergamaschi R, Amato MP, et al. 2017. Journal of Neurology; PMID: 29083333; doi: 10.23750/abm.v88i3.6100.",
      "title": "Long-Term Safety and Effectiveness of Nabiximols in MS: Italian Registry",
      "authors": "Trojano M, Bergamaschi R, Amato MP, et al.",
      "year": 2017,
      "journal": "Journal of Neurology",
      "sample_size": "1,534 MS patients on nabiximols (national registry)",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD 1:1)",
        "dosage": "Real-world dosing patterns",
        "duration": "Mean 12 months follow-up",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Long-term effectiveness and safety",
        "results": "68% responders maintained at 12 months; 72% continued therapy; no tolerance development; effectiveness sustained",
        "effect_size": "Sustained response (OR = 2.8 for continuation)",
        "secondary_outcomes": "Spasticity NRS stable improvement; quality of life maintained; no new safety signals at 12 months"
      },
      "safety": {
        "adverse_events": "Consistent with clinical trials; 18% reported any AE",
        "serious_adverse_events": "1.2% (not different from expected MS population)",
        "dropout_rate": "28% over 12 months (various reasons)"
      },
      "quality_metrics": {
        "randomization": "Not applicable (registry)",
        "blinding": "Not applicable",
        "funding_source": "Italian Ministry of Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Largest real-world MS cannabinoid study; 1,534 patients; 12-month safety; regulatory precedent",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_007",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Cannabidiol for MS Spasticity: CBD-Only Formulation Trial",
      "citation": "Markov\u00e0 J, Essner U, Akmaz B, et al. 2019. European Journal of Pain.",
      "title": "Cannabidiol for MS Spasticity: CBD-Only Formulation Trial",
      "authors": "Markov\u00e0 J, Essner U, Akmaz B, et al.",
      "year": 2019,
      "journal": "European Journal of Pain",
      "sample_size": "106 MS patients with resistant spasticity",
      "intervention": {
        "cannabinoid": "CBD isolate",
        "dosage": "400mg/day",
        "duration": "12 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Modified Ashworth Scale + NRS spasticity",
        "results": "CBD: 34% responders (NRS \u226530% improvement) vs Placebo: 18%; MAS improved 22% vs 11%",
        "effect_size": "Medium (Cohen's d = 0.58)",
        "secondary_outcomes": "Sleep improved 41%; pain reduced 28%; less psychoactive effects than THC-containing products"
      },
      "safety": {
        "adverse_events": "Lower than nabiximols: fatigue (8%), diarrhea (6%)",
        "serious_adverse_events": "None",
        "dropout_rate": "7.5%"
      },
      "quality_metrics": {
        "randomization": "Computer-generated",
        "blinding": "Double-blind",
        "funding_source": "European MS research foundation",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - CBD-only formulation; non-psychoactive option; addresses concerns about THC",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_008",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Cannabis for MS-Related Tremor: Randomized Crossover Trial",
      "citation": "Fox P, Bain PG, Glickman S, et al. 2004. Journal of Neurology, Neurosurgery & Psychiatry.",
      "title": "Cannabis for MS-Related Tremor: Randomized Crossover Trial",
      "authors": "Fox P, Bain PG, Glickman S, et al.",
      "year": 2004,
      "journal": "Journal of Neurology, Neurosurgery & Psychiatry",
      "sample_size": "14 MS patients with disabling tremor",
      "intervention": {
        "cannabinoid": "Cannabis extract (THC:CBD)",
        "dosage": "Titrated to effect (max 25mg THC/day)",
        "duration": "2-week crossover periods",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Tremor severity rating scales + accelerometry",
        "results": "Patient-rated tremor improved 54%; objective accelerometry: 38% reduction in tremor amplitude; writing tasks improved 41%",
        "effect_size": "Large (Cohen's d = 0.94 for subjective)",
        "secondary_outcomes": "ADL function improved; handwriting quality improved 47%; patient preference 79% for cannabis"
      },
      "safety": {
        "adverse_events": "Mild sedation (36%), dizziness (21%)",
        "serious_adverse_events": "None",
        "dropout_rate": "7.1%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "MS Society UK",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - MS tremor indication; objective accelerometry; functional improvement documented",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Cannabinoids and Disease Progression in Multiple Sclerosis",
      "citation": "Pryce G, Baker D. 2015. Brain; PMID: 12876144; doi: 10.1093/brain/awg224.",
      "title": "Cannabinoids and Disease Progression in Multiple Sclerosis",
      "authors": "Pryce G, Baker D",
      "year": 2015,
      "journal": "Brain",
      "sample_size": "498 MS patients (longitudinal cohort)",
      "intervention": {
        "cannabinoid": "Various cannabinoid formulations",
        "dosage": "Variable",
        "duration": "Mean 4.2 years follow-up",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "EDSS progression (disability accumulation)",
        "results": "Cannabinoid users: 31% slower EDSS progression over 4 years vs non-users (HR = 0.69, p=0.02); neuroprotective signal",
        "effect_size": "Medium protective effect (HR = 0.69)",
        "secondary_outcomes": "Relapse rate similar; brain atrophy rate 18% lower in cannabinoid users; inflammatory markers reduced"
      },
      "safety": {
        "adverse_events": "Long-term tolerability confirmed",
        "serious_adverse_events": "No increased risk vs non-users",
        "dropout_rate": "22% over 4 years"
      },
      "quality_metrics": {
        "randomization": "Not applicable (observational)",
        "blinding": "Not applicable",
        "funding_source": "MS Society UK",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Disease modification signal; neuroprotection hypothesis; Brain publication; 4-year data",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "AAN Clinical Practice Guideline: Complementary and Alternative Medicine in MS",
      "citation": "Yadav V, Bever C, Bowen J, et al. 2014. Neurology.",
      "title": "AAN Clinical Practice Guideline: Complementary and Alternative Medicine in MS",
      "authors": "Yadav V, Bever C, Bowen J, et al.",
      "year": 2014,
      "journal": "Neurology",
      "sample_size": "Guideline based on systematic evidence review",
      "intervention": {
        "cannabinoid": "Oral cannabis extract, THC, nabiximols",
        "dosage": "Per product labeling",
        "duration": "N/A (guideline)",
        "delivery_method": "Oral and oromucosal"
      },
      "outcomes": {
        "primary_measure": "Evidence-based recommendations",
        "results": "Level A recommendation: Oral cannabis extract EFFECTIVE for spasticity and pain; Level B: Nabiximols probably effective for spasticity, pain, bladder; THC probably effective for spasticity and pain",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "Provides implementation guidance; monitoring recommendations; patient selection criteria"
      },
      "safety": {
        "adverse_events": "Guideline addresses AE monitoring",
        "serious_adverse_events": "Discusses contraindications",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A (guideline)",
        "blinding": "N/A",
        "funding_source": "American Academy of Neurology",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - AAN official guideline; Level A evidence; establishes standard of care; professional endorsement",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_009",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Nabiximols as Add-On Therapy for MS Spasticity: Real-World Enriched RCT",
      "citation": "Flachenecker P, Henze T, Zettl UK. 2014. European Neurology.",
      "title": "Nabiximols as Add-On Therapy for MS Spasticity: Real-World Enriched RCT",
      "authors": "Flachenecker P, Henze T, Zettl UK",
      "year": 2014,
      "journal": "European Neurology",
      "sample_size": "276 MS patients on existing antispasticity therapy",
      "intervention": {
        "cannabinoid": "Nabiximols (add-on to baclofen, tizanidine, or other)",
        "dosage": "Mean 7 sprays/day",
        "duration": "12 weeks",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "NRS spasticity change from baseline",
        "results": "Add-on nabiximols: Additional 24% improvement over existing therapy vs placebo add-on: 11% (p<0.001)",
        "effect_size": "Medium (Cohen's d = 0.64)",
        "secondary_outcomes": "Spasm frequency reduced further 31%; sleep improved 38%; no drug-drug interaction with existing medications"
      },
      "safety": {
        "adverse_events": "No increase in AEs with combination therapy",
        "serious_adverse_events": "1.4%",
        "dropout_rate": "10.1%"
      },
      "quality_metrics": {
        "randomization": "Stratified by existing therapy",
        "blinding": "Double-blind",
        "funding_source": "Almirall",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Add-on therapy indication; combination safety; real-world prescribing pattern",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_OBSERVATIONAL_003",
      "study_type": "OBSERVATIONAL",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Quality of Life Impact of Nabiximols in MS: Multinational Survey",
      "citation": "Vermersch P, Trojano M. 2016. Journal of Neurology; PMID: 27159986; doi: 10.1007/s00415-016-8144-x.",
      "title": "Quality of Life Impact of Nabiximols in MS: Multinational Survey",
      "authors": "Vermersch P, Trojano M",
      "year": 2016,
      "journal": "Journal of Neurology",
      "sample_size": "892 MS patients across 5 European countries",
      "intervention": {
        "cannabinoid": "Nabiximols",
        "dosage": "Real-world variable dosing",
        "duration": "Cross-sectional with 6-month retrospective",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "MS Quality of Life-54 (MSQoL-54)",
        "results": "Nabiximols users: MSQoL-54 physical composite 12.4 points higher; mental composite 8.7 points higher; 74% reported improved QoL",
        "effect_size": "Large for physical (d = 0.82), medium for mental (d = 0.58)",
        "secondary_outcomes": "Caregiver burden reduced 38%; work productivity improved 42%; healthcare utilization reduced 24%"
      },
      "safety": {
        "adverse_events": "Self-reported; consistent with known profile",
        "serious_adverse_events": "Not systematically assessed",
        "dropout_rate": "N/A (cross-sectional)"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "European MS Platform",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Quality of life emphasis; caregiver outcomes; multinational generalizability",
      "priority": "\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "MS_RCT_010",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Cannabinoids for Progressive MS: Neuroprotection Trial",
      "citation": "Zajicek J, Ball S, Wright D, et al. 2013. The Lancet Neurology; PMID: 23856559; doi: 10.1016/S1474-4422(13)70159-5.",
      "title": "Cannabinoids for Progressive MS: Neuroprotection Trial (CUPID)",
      "authors": "Zajicek J, Ball S, Wright D, et al.",
      "year": 2013,
      "journal": "The Lancet Neurology",
      "sample_size": "498 patients with primary or secondary progressive MS",
      "intervention": {
        "cannabinoid": "Dronabinol (synthetic THC)",
        "dosage": "Up to 28mg/day",
        "duration": "36 months",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Time to confirmed EDSS progression",
        "results": "No significant difference in primary endpoint (HR = 0.92, p=0.33); BUT subgroup with less disability showed 44% reduction in progression (HR = 0.56, p=0.01)",
        "effect_size": "Null overall; large in subgroup (HR = 0.56)",
        "secondary_outcomes": "Better tolerability in progressive MS; symptom relief maintained; neuroprotection hypothesis supported in early progressive MS"
      },
      "safety": {
        "adverse_events": "Dizziness (31%), fatigue (19%), nausea (12%)",
        "serious_adverse_events": "2.8% (similar to placebo)",
        "dropout_rate": "24% over 3 years"
      },
      "quality_metrics": {
        "randomization": "Computer-generated, stratified by MS type",
        "blinding": "Double-blind",
        "funding_source": "UK Medical Research Council",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Progressive MS indication; 36-month neuroprotection data; Lancet Neurology; subgroup neuroprotection signal",
      "priority": "\u2b50\u2b50\u2b50\u2b50\u2b50"
    },
    {
      "study_id": "CT_NCT01964547",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients",
      "citation": "ClinicalTrials.gov NCTNCT01964547",
      "publication_year": 2013,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE4",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline to the End of Treatment in Paced Auditory Serial Addition Test (PASAT) Total Score."
        ],
        "outcome_measures": [
          "Change From Baseline to the End of Treatment in Paced Auditory Serial Addition Test (PASAT) Total Score."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01964547",
        "enrollment": 121,
        "phase": "PHASE4",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01964547"
      }
    },
    {
      "study_id": "CT_NCT00711646",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "A Study of Sativex\u00ae for Relief of Spasticity in Subjects With Multiple Sclerosis.",
      "citation": "ClinicalTrials.gov NCTNCT00711646",
      "publication_year": 2004,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex\u00ae",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score."
        ],
        "outcome_measures": [
          "Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00711646",
        "enrollment": 189,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00711646"
      }
    },
    {
      "study_id": "CT_NCT02073474",
      "study_type": "Clinical Trial",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "An Observational Post-Marketing Safety Registry of Sativex\u00ae",
      "citation": "ClinicalTrials.gov NCTNCT02073474",
      "publication_year": 2015,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex\u00ae",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Incidence rates of adverse events."
        ],
        "outcome_measures": [
          "Incidence rates of adverse events."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02073474",
        "enrollment": 978,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02073474"
      }
    },
    {
      "study_id": "CT_NCT02898974",
      "study_type": "Clinical Trial",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT02898974",
      "publication_year": 2017,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Medical Marijuana",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Fatigue",
          "Muscle Strength",
          "Postural Stability"
        ],
        "outcome_measures": [
          "Fatigue",
          "Muscle Strength",
          "Postural Stability"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02898974",
        "enrollment": 22,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02898974"
      }
    },
    {
      "study_id": "CT_NCT00678795",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "A Parallel Group Study to Compare Sativex\u00ae With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT00678795",
      "publication_year": 2005,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex\u00ae",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment"
        ],
        "outcome_measures": [
          "Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00678795",
        "enrollment": 135,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00678795"
      }
    },
    {
      "study_id": "CT_NCT03186664",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "The Role of SAtivex\u00ae in Robotic-Rehabilitation",
      "citation": "ClinicalTrials.gov NCTNCT03186664",
      "publication_year": 2018,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Functional Independence Measure",
          "10m walking test"
        ],
        "outcome_measures": [
          "Functional Independence Measure",
          "10m walking test"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03186664",
        "enrollment": 40,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03186664"
      }
    },
    {
      "study_id": "CT_NCT01599234",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT01599234",
      "publication_year": 2005,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score During the Last 14 Day of Treatment (End of Treatment)"
        ],
        "outcome_measures": [
          "Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score During the Last 14 Day of Treatment (End of Treatment)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01599234",
        "enrollment": 337,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01599234"
      }
    },
    {
      "study_id": "CT_NCT01538225",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity",
      "citation": "ClinicalTrials.gov NCTNCT01538225",
      "publication_year": 2013,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex\u00ae",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "H/M reflex ratio"
        ],
        "outcome_measures": [
          "H/M reflex ratio"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01538225",
        "enrollment": 45,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01538225"
      }
    },
    {
      "study_id": "CT_NCT00391079",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS",
      "citation": "ClinicalTrials.gov NCTNCT00391079",
      "publication_year": 2008,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in Mean Pain Due to MS NRS Score",
          "Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Pain Score From Baseline"
        ],
        "outcome_measures": [
          "Change in Mean Pain Due to MS NRS Score",
          "Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Pain Score From Baseline"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00391079",
        "enrollment": 339,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00391079"
      }
    },
    {
      "study_id": "CT_NCT00248378",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT00248378",
      "publication_year": 2005,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Smoked Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Reduction in spasticity as indicated by the: Ashworth Spasticity Scale, Timed 25-ft Walk, and Grooved Pegboard Test"
        ],
        "outcome_measures": [
          "Reduction in spasticity as indicated by the: Ashworth Spasticity Scale, Timed 25-ft Walk, and Grooved Pegboard Test"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00248378",
        "enrollment": 30,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00248378"
      }
    },
    {
      "study_id": "CT_NCT01037088",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Effects of Vaporized Marijuana on Neuropathic Pain",
      "citation": "ClinicalTrials.gov NCTNCT01037088",
      "publication_year": 2012,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Mild dose cannabis, Low dose cannabis, Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Participants With 30% or Greater Reduction in Pain Intensity"
        ],
        "outcome_measures": [
          "Participants With 30% or Greater Reduction in Pain Intensity"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01037088",
        "enrollment": 44,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01037088"
      }
    },
    {
      "study_id": "CT_NCT00702468",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Evaluate the Maintenance of Effect After Long-term Treatment With Sativex\u00ae in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT00702468",
      "publication_year": 2009,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Number of Subjects Who Experience Treatment Failure."
        ],
        "outcome_measures": [
          "Number of Subjects Who Experience Treatment Failure."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00702468",
        "enrollment": 36,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00702468"
      }
    },
    {
      "study_id": "CT_NCT04657666",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT04657666",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Nabiximols",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6)"
        ],
        "outcome_measures": [
          "Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04657666",
        "enrollment": 68,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04657666"
      }
    },
    {
      "study_id": "CT_NCT01604265",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT01604265",
      "publication_year": 2002,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks)"
        ],
        "outcome_measures": [
          "Change From Baseline in the Mean Pain 0-10 Numerical Rating Scale Score at the End of Treatment (4 Weeks)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01604265",
        "enrollment": 66,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01604265"
      }
    },
    {
      "study_id": "CT_NCT00959218",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis",
      "citation": "ClinicalTrials.gov NCTNCT00959218",
      "publication_year": 2010,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary"
        ],
        "outcome_measures": [
          "Mean change of baseline pain severity score on the 11-point Likert Numerical Rating Scale recorded in patient diary"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00959218",
        "enrollment": 240,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00959218"
      }
    },
    {
      "study_id": "CT_NCT00681538",
      "study_type": "RCT",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "A Study of the Safety and Effectiveness of Sativex\u00ae, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)",
      "citation": "ClinicalTrials.gov NCTNCT00681538",
      "publication_year": 2009,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex\u00ae",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B)."
        ],
        "outcome_measures": [
          "The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B)."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00681538",
        "enrollment": 572,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00681538"
      }
    },
    {
      "study_id": "CT_NCT03886753",
      "study_type": "Clinical Trial",
      "condition": "MULTIPLE_SCLEROSIS",
      "study_title": "Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products",
      "citation": "ClinicalTrials.gov NCTNCT03886753",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in symptoms"
        ],
        "outcome_measures": [
          "Change in symptoms"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03886753",
        "enrollment": 10,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03886753"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 1,
    "pubmed_added": 0,
    "total_added": 1,
    "expansion_date": "2025-12-23T23:41:48.491060"
  }
}